Literature DB >> 31186841

The horizon: New targets and new agents.

Alison B Jazwinski1, Andrew J Muir1.   

Abstract

Year:  2012        PMID： 31186841      PMCID： PMC6490693          DOI： 10.1002/cld.2

Source DB:  PubMed          Journal:  Clin Liver Dis (Hoboken)        ISSN： 2046-2484


× No keyword cloud information.
  19 in total

Review 1.  Non-nucleoside inhibitors of the HCV polymerase.

Authors:  Robert T Sarisky
Journal:  J Antimicrob Chemother       Date:  2004-06-09       Impact factor: 5.790

Review 2.  Cyclophilin inhibitors for the treatment of HCV infection.

Authors:  Gunter Fischer; Philippe Gallay; Sam Hopkins
Journal:  Curr Opin Investig Drugs       Date:  2010-08

Review 3.  Resistance to direct antiviral agents in patients with hepatitis C virus infection.

Authors:  Christoph Sarrazin; Stefan Zeuzem
Journal:  Gastroenterology       Date:  2009-12-16       Impact factor: 22.682

Review 4.  Review article: specifically targeted anti-viral therapy for hepatitis C - a new era in therapy.

Authors:  C M Lange; C Sarrazin; S Zeuzem
Journal:  Aliment Pharmacol Ther       Date:  2010-03-31       Impact factor: 8.171

Review 5.  The hepatitis C virus life cycle as a target for new antiviral therapies.

Authors:  Jean-Michel Pawlotsky; Stéphane Chevaliez; John G McHutchison
Journal:  Gastroenterology       Date:  2007-05       Impact factor: 22.682

6.  Telaprevir and peginterferon with or without ribavirin for chronic HCV infection.

Authors:  Christophe Hézode; Nicole Forestier; Geoffrey Dusheiko; Peter Ferenci; Stanislas Pol; Tobias Goeser; Jean-Pierre Bronowicki; Marc Bourlière; Shahin Gharakhanian; Leif Bengtsson; Lindsay McNair; Shelley George; Tara Kieffer; Ann Kwong; Robert S Kauffman; John Alam; Jean-Michel Pawlotsky; Stefan Zeuzem
Journal:  N Engl J Med       Date:  2009-04-30       Impact factor: 91.245

7.  Diagnosis, management, and treatment of hepatitis C: an update.

Authors:  Marc G Ghany; Doris B Strader; David L Thomas; Leonard B Seeff
Journal:  Hepatology       Date:  2009-04       Impact factor: 17.425

8.  Inhibition of native hepatitis C virus replicase by nucleotide and non-nucleoside inhibitors.

Authors:  Han Ma; Vincent Leveque; Anniek De Witte; Weixing Li; Than Hendricks; Saundra M Clausen; Nick Cammack; Klaus Klumpp
Journal:  Virology       Date:  2005-02-05       Impact factor: 3.616

Review 9.  HCV antiviral resistance: the impact of in vitro studies on the development of antiviral agents targeting the viral NS5B polymerase.

Authors:  Licia Tomei; Sergio Altamura; Giacomo Paonessa; Raffaele De Francesco; Giovanni Migliaccio
Journal:  Antivir Chem Chemother       Date:  2005

10.  GT-1a or GT-1b subtype-specific resistance profiles for hepatitis C virus inhibitors telaprevir and HCV-796.

Authors:  Matthew F McCown; Sonal Rajyaguru; Simran Kular; Nick Cammack; Isabel Nájera
Journal:  Antimicrob Agents Chemother       Date:  2009-03-09       Impact factor: 5.191
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.